Search
Flutamide
go.drugbank.com/drugs/DB00499ApprovedInvestigationalAn antiandrogen with about the same potency as cyproterone in rodent and canine species.
Aclidinium
go.drugbank.com/drugs/DB08897ApprovedAclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). … It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Pyrvinium
go.drugbank.com/drugs/DB06816ApprovedInvestigationalWithdrawnPyrvinium is an anthelmintic effective for pinworms. Several forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and pamoate.
Suvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Cyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnIt may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.
Embusartan
go.drugbank.com/drugs/DB19949ExperimentalEmbusartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Embusartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).
Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor BlockersZalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnIts principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. … A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen.
Phenacemide
go.drugbank.com/drugs/DB01121ApprovedPhenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures.
Lumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnNew Zealand and Canada have also followed suit in recalling the drug. … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver
Vilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone was given FDA approval on January 21, 2011[L6046,A177622]. … Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622].